St. Louis, Feb. 8, 2005 --A new study has shown a stroke-prevention drug designed to be an improvement over prior treatments is less cost-effective for most patients than warfarin, the blood thinner with a 50-year history of helping prevent blood clots and strokes. The study, conducted by researchers at Washington University School of Medicine in St. Louis found, however, that the new drug would be cost-effective for those atrial fibrillation patients whose risk of bleeding is high.
The findings are reported in the February 9 issue of the Journal of the American Medical Association.
In patients with atrial fibrillation, the upper part of the heart often quivers instead of beating, so blood pools and clots in the upper chambers. The blood clots tend to be large and can travel to the brain causing massive strokes.
AstraZeneca, the company that developed Exanta, had submitted a New Drug Application to the Food and Drug Administration for approval of the drug as an agent to prevent strokes in patients with atrial fibrillation as well as to prevent blood clots in other conditions. The drug was intended as an alternative to warfarin.
In October 2004, the FDA denied Exanta approval. The agency noted that Exanta carried a small risk of liver damage and cited insufficient evidence that it was as effective as warfarin for preventing strokes.
"Warfarin is extremely effective," says lead author Brian F. Gage, M.D., associate professor of medicine. "It lowers the risk of stroke by 65 percent. Unfortunately, patients have different sensitivities to warfarin, so it's difficult to adjust the dose, especially when initiating the drug. While they're on warfarin, patients' blood clotting has to be monitored often, and patients find that inconvenient. Warfarin also interacts with various foods and other drugs. Moreover, it doubles the risk of hemorrhage."
Before Exanta, the alternative for patients unable to tolerate warfarPage: 1 2 3 Related medicine news :1
Contact: Gwen Ericson
Washington University School of Medicine
. Studies led by Mount Sinai researchers reinforces potential benefits of new stroke-prevention drug2
. Study suggests brain haemorrhage in babies over age one month unlikely from traumatic delivery3
. People are unlikely to withdraw consent for genetic research4
. Limitations of current evaluation techniques for the cost-effectiveness of treatments5
. Antiplatelet drug found to reduce risk of recurrent heart attacks and stroke is cost-effective6
. Newborn screening is cost-effective in detecting rare but treatable genetic disease7
. Stanford computer model shows bypass surgery more cost-effective than stents8
. Treating older adults for flu is cost-effective, but preventing it with a yearly flu shot is better9
. Colonoscopy far more cost-effective against colon cancer than promising Cox II drugs, study predicts10
. Economic evaluation shows add-on therapy with Keppra(r) is a cost-effective alternative11
. Drotrecogin alfa (activated) is a cost-effective treatment for severe sepsis patients